Phase 1 XmAb819 results in advanced clear cell renal cell carcinoma drive relevance.
Context
What happened: Xencor, Inc. ($XNCR) discussed Phase 1 results for XmAb819 in advanced clear cell renal cell carcinoma, publishing a slide deck in conjunction with the event.
Why it matters: The content does not state any consequence, analyst reaction, or market move, so no significance can be reported from it.
Key numbers: Phase 1.
What changed
Xencor, Inc. ($XNCR) discussed Phase 1 results for XmAb819 in advanced clear cell renal cell carcinoma, publishing a slide deck in conjunction with the event.
Why it matters
The content does not state any consequence, analyst reaction, or market move, so no significance can be reported from it.
Key numbers: Phase 1.
← Dashboard
Oct 27, 2026 01:19 PM ET